|
Aug 14
|
Sector Update: Health Care Stocks Rise Late Afternoon
|
|
Aug 10
|
uniQure N.V. (NASDAQ:QURE) is favoured by institutional owners who hold 55% of the company
|
|
Jul 31
|
Wall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a Bet
|
|
Jul 29
|
uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates
|
|
Jul 29
|
uniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company Progress
|
|
Jul 22
|
Investors Look Ahead to Powell's Remarks as US Futures Mostly Lower Tuesday Pre-Bell
|
|
Jul 22
|
uniQure to Announce Second Quarter 2025 Financial Results
|
|
Apr 17
|
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
|
|
Feb 20
|
uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%
|
|
Feb 7
|
uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
|
|
Feb 7
|
CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
|
|
Jan 8
|
uniQure Announces Pricing of its Public Offering
|
|
Jan 7
|
uniQure Announces Proposed Public Offering
|
|
Sep 23
|
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease
|
|
Aug 3
|
uniQure N.V. (NASDAQ:QURE) Analysts Are Cutting Their Estimates: Here's What You Need To Know
|
|
Aug 1
|
UniQure restructuring to claim 300 jobs
|
|
Aug 1
|
UniQure (QURE) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 1
|
UniQure: Q2 Earnings Snapshot
|
|
Aug 1
|
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update
|
|
Jul 26
|
Wall Street Analysts See a 125.9% Upside in uniQure (QURE): Can the Stock Really Move This High?
|